InterMune Inc. announced in a press release the issuance of US Patent Number 7,491,794, a composition of matter patent which covers the ITMN-191 (R7227) compound.
The nominal 20-year patent term extends to October 13, 2024. ITMN-191 is an inhibitor of the hepatitis C virus (HCV) NS3/4A protease.
"We are pleased to announce that this new patent, which is the foundation of our intellectual property coverage of ITMN-191, has issued,” InterMune Chairman, CEO and President Dan Welch said.
“We look forward to continued progress in developing ITMN-191 with our partner, Roche, as we anticipate the start of our Phase 2b program in the second quarter of 2009," he added.
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology.
SOURCE:AGIPNEWS